Dengue and dengue haemorrhagic fever

Lancet

Volumn 352, Issue 9132, 1998, Pages 971-977

  Rigau Pérez, José G ^a,c   Clark, Gary G ^a   Gubler, Duane J ^b   Reiter, Paul ^a   Sanders, Eduard J ^a   Vorndam, A Vance ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (Puerto Rico)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c CDC Dengue Branch   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ARTHRALGIA; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; FEVER; FLUID THERAPY; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEMORRHAGIC FEVER; HUMAN; INFECTION RISK; MORBIDITY; MOSQUITO; MYALGIA; NONHUMAN; PRIORITY JOURNAL; SUPERINFECTION; TRAVEL; VECTOR CONTROL; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 0032547502     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)12483-7     Document Type: Review

References (83)

1. 1 Gubler DJ. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever, Wallingford, UK: CAB International, 1997: 1-22.
2. 2 Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995; 1: 55-57.
3. 3 Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997; 50: 161-69.
4. 4 World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment and control. Geneva: WHO, 1986: 7-15.
5. 5 Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Am J Trop Med Hyg 1989; 40: 571-78.
6. 6 Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176: 313-21.
7. 7 Cobra C, Rigau-Pérez JG, Kuno G, Vorndam V. Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990-1991. Am J Epidemiol 1995; 142: 1204-11.
8. 8 Gubler DJ, Suharyono W, Tan T, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. Bull WHO 1981; 59: 623-30.
9. 9 Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176: 322-30.
10. 10 Burke DS, Nisalak A, Johnson DE, et al. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38: 172-80.
11. 11 Kuberski T, Rosen L, Reed D, et al. Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji. Am J Trop Med Hyg 1977; 26: 775-83.
12. 12 Dietz VJ, Gubler DJ, Ortiz S, et al. The 1986 dengue and dengue hemorrhagic fever outbreak in Puerto Rico: epidemiologic and clinical observations. PR Health Sci J 1996; 15: 201-10.
13. 13 Trofa AF, DeFraites RF, Smoak BL, et al. Dengue in US military personnel in Haiti. JAMA 1997; 277: 1546-48.
14. 14 Nimmannitya S. Dengue fever/dengue haemorrhagic fever: case management. Trop Med (Nagasaki) 1994; 36: 249-56.
15. 15 Halstead SB. Dengue and hemorrhagic fevers of southeast Asia. Yale J Biol Med 1965; 37: 434-54.
16. 16 Nimmannitya S, Halstead SB, Cohen SN, Margiotta MR. Dengue and chikungunya virus infection in man in Thailand, 1962-64 I: observations on hospitalized patients with hemorrhagic fever. Am J Trop Med Hyg 1969; 18: 954-71.
17. 17 Pan American Health Organization. Dengue and dengue hemorrhagic fever in the Americas: guidelines for prevention and control. Washington, DC: PAHO Sci Publ no 548: 1994: 3-20, 49-58, 69-70.
18. 18 Martínez Torres E. Dengue y dengue hemorrágico: aspectos clínicos. Salud Pública Mex 1995; 37 (suppl): 29-44.
19. 19 Chaturvedi UC, Dhawan R, Mukerjee R. Immunosuppression and cytotoxicity of dengue infection in the mouse model. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 291-311.
20. 20 Tassniyom S, Vasanawathana S, Dhiensiri T, Nisalak A, Chirawatkul A. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial. J Pediatr 1997; 131: 525-28.
21. 21 Rigau-Pérez JG and the Puerto Rico Association of Epidemiologists. The clinical manifestations of dengue hemorrhagic fever in Puerto Rico, 1990-91. Pan Am J Public Health 1997; 1: 381-88.
22. 22 Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 1993; 92: 111-15.
23. 23 Sumarmo, Wulur H, Jahja E, Gubler DJ, Suharyono W, Sorensen K. Clinical observations on virologically confirmed fatal dengue infections in Jakarta, Indonesia. Bull WHO 1983; 61: 693-701.
24. 24 Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unsual manifestations. Southeast Asian J Trop Med Pub Hlth 1987; 18: 398-406.
25. 25 Thisyakorn U, Thisyakorn C. Dengue infections with unusual manifestations. J Med Assoc Thai 1994; 77: 410-13.
26. 26 Lam SK. Dengue infections with central nervous system manifestations. Neurol J Southeast Asia 1996; 20: 3-6.
27. 27 Lum LSC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity? Am J Trop Med Hyg 1996; 54: 256-59.
28. 28 Chye JK, Lim CT, Ng KB, Lim JMH, George R, Lam SK. Vertical transmission of dengue. Clin Infect Dis 1997; 25: 1374-77.
29. 29 de Wazières B, Gil H, Vuitton DA, Dupond J-L. Nosocomial transmission of dengue from a needlestick injury. Lancet 1998; 351: 498.
30. 30 Laferl H. Pleural effusion and ascites on return from Pakistan. Lancet 1997; 350: 1072.
31. 31 Gubler DJ, Kuno G, Sather GE, et al. Mosquito cell cultures and specific monocloal antibodies in surveillance for dengue viruses. Am J Trop Med Hyg 1984; 33: 158-65.
32. 32 Vorndam V, Kuno G. Diagnosis of dengue virus infections. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 313-33.
33. 33 Lanciotti RS, Calisher CH, Gubler DJ, et al. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992; 30: 545-51.
34. 34 Brown JL, Wilkinson R, Davidson RN, et al. Rapid diagnosis and determination of duration of viraemia in dengue fever using a reverse transcriptase polymerase chain reaction. Trans R Soc Trop Med Hyg 1996; 90: 140-43.
35. 35 Burke DS, Nisalak A, Ussery MA. Antibody capture immunoassay detection of Japanese encephalitis virus immunoglobulin M and G antibodies in cerebrospinal fluid. J Clin Microbiol 1982; 16: 1034-42.
36. 36 Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40: 418-27.
37. 37 Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med and Hyg 1958; 7: 561-77.
38. 38 Chungue E, Marche G, Pichart R, et al. Comparison of immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) and hemagglutination inhibition (HI) test for the detection of dengue antibodies: prevalence of dengue IgG-ELISA antibodies in Tahiti. Trans R Soc Trop Med Hyg 1989; 83: 708-71.
39. 39 Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99: 291-96.
40. 40 Gubler DJ, Rosen L. A simple technique for demonstrating transmission of dengue virus by mosquitoes without the use of vertebrate hosts. Am J Trop Med Hyg 1976; 25: 146-50.
41. 41 Putnam JL, Scott TW. The effect of multiple host contacts on the infectivity of dengue-2 virus-infected Aedes aegypti. J Parasitol 1995; 81: 170-74.
42. 42 CDC. Dengue type 3 infection - Nicaragua and Panama, October-November 1994. MMWR 1995; 44: 21-24.
43. 43 Guzmán MG, Vázquez S, Martinez E, et al. Dengue in Nicaragua, 1994: reintroduction of serotype 3 in the Americas. Pan Am J Public Health 1997; 1: 193-99.
44. 44 Briseño-García B, Gómez-Dantés H, Argott-Ramírez E, et al. Potential risk for dengue hemorrhagic fever: the isolation of serotype dengue-3 in Mexico. Emerg Inf Dis 1996; 2: 133-35.
45. 45 Koopman JS, Prevots DR, Vaca Marin MA, et al. Determinants and predictors of dengue infection in Mexico. Am J Epidemiol 1991; 133: 1168-78.
46. 46 Newton EAC, Reiter P. A model of the transmission of dengue fever with an evaluation of the impact of ultra-low volume (ULV) insecticide applications on dengue epidemics. Am J Trop Med Hyg 1992; 47: 709-20.
47. 47 Focks DA, Daniels E, Haile DG, Keesling JE. A simulation model of the epidemiology of urban dengue fever: literature analysis, model development, preliminary validation, and samples of simulation results. Am J Trop Med Hyg 1995; 54: 489-506.
48. 48 Halstead SB, Udomsakdi S, Singharaj P, Nisalak A. Dengue and chikungunya virus infection in man in Thailand, 1962-64 III: clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am J Trop Med Hyg 1969; 18: 984-96.
49. 49 Sharp TW, Wallace MR, Hayes CG, et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995; 53: 89-94.
50. 50 Karp BE. Dengue fever: a risk to travelers. Maryland Med J 1997; 46: 299-302.
51. 51 Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239: 476-81.
52. 52 Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230: 244-51.
53. 53 Halstead SB. Epidemiology of dengue and dengue hemorrhagic fever. In: Gubler DJ, Kuno G. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 23-44.
54. 54 Kliks SC, Nimmanitya S, Nisalak A, et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38: 411-19.
55. 55 Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead S. Risk factors in dengue shock syndrome: a prospective epidemiological study in Rayong, Thailand I: the 1980 outbreak. Am J Epidemiol 1984; 120: 653-69.
56. 56 Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenic cascade. Ref Inf Dis 1989; 11 (suppl 4): S830-39.
57. 57 Hober D, Poli L, Roblin B, et al. Serum levels of tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and interleukin-1β (IL-1α) in dengue-infected patients. Am J Trop Med Hyg 1993; 48: 324-31.
58. 58 Kurane I, Rothman AL, Livingston PG, et al. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol 1994; 9 (suppl) 59-64.
59. 59 Gubler DJ, Reed D, Rosen L, Hitchcock Jr, JC. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 1978; 27: 581-89.
60. 60 Gubler DJ, Suharyono W, Lubis I, Eram S, Gunarso S. Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg 1981; 30: 1094-99.
61. 61 Scott RMcN, Nimmanitya S, Bancroft WH, et al. Shock syndrome in primary dengue infections. Am J Trop Med Hyg 1976; 25: 866-74.
62. 62 Thisyakorn U, Nimmanitya S. Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993; 16: 295-97.
63. 63 Bravo JR, Guzmán MG, Kourí GP. Why dengue haemorrhagic fever in Cuba? I: individual risk factors for fengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans Royal Soc Trop Med Hyg 1987; 81: 816-20.
64. 64 Morier L, Kouri-Flores G, Guzmán Tirado G, Soler-Nodarse M. Antibody-dependent enhancement of dengue-2 virus in people of white descent in Cuba. Lancet 1987; i: 1028-29.
65. 65 Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. International, Wallingford, UK: CAB International 1997: 367-77.
66. 66 Kinney RM, Butrapet S, Chang GJ, et al. Construction of infectious cDNA for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997; 230: 300-08.
67. 67 Trent DW, Kinney RM, Huang CY-H. Recombinant dengue virus vaccines. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 379-403.
68. 68 Chambers TJ, Tsai TF, Pervokov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 1997; 15: 1494-502.
69. 69 Reiter P, Gubler DJ. Surveillance and control of urban dengue vectors. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 425-62.
70. 70 Gubler DJ, Clark GG. Community-based integrated control of Aedes aegypti: a brief overview of current programs. Am J Trop Med Hyg 1994; 50 (suppl 6): 50-60.
71. 71 Winch P, Kendall C, Gubler DJ. Effectiveness of community participation in vector-borne disease control. Health Policy Planning 1992; 7: 342-51.
72. 72 Rosenbaum J, Nathan MB, Ragoonanansingh R, et al. Community participation in dengue prevention and control: a survey of knowledge, attitudes and practice in Trinidad and Tobago. Am J Trop Med Hyg 1995; 53: 111-17.
73. 73 Gordon AJ, Rojas Z, Tidwell M. Cultural factors in Aedes aegypti and dengue control in Latin America: a case study from the Dominican Republic. Int Quart Community Hlth Educ 1990; 10: 193-211.
74. 74 Winch P, Lloyd L, Godas MD, Kendall C. Beliefs about the prevention of dengue and other febrile illnesses in Merida, Mexico. J Trop Med Hyg 1991; 94: 377-87.
75. 75 Whiteford LM. The ethnoecology of dengue fever. Med Anthropol Q 1997; 11: 202-23.
76. 76 Lloyd LS, Winch P, Ortega-Canto J, Kendall C. The design of a community-based health education intervention for the control of Aedes aegypti. Am J Trop Med Hyg 1994; 50: 401-11.
77. 77 Winch P, Lloyd LS, Hoemeke L, Leontsini E. Vector control at the household level: an analysis of its impact on women. Acta Trop 1994; 56: 327-39.
78. 78 Gordon AJ. Mixed strategies in health education and community participation: an evaluation of dengue control in the Dominican Republic. Health Educ Res 1998; 3: 399-419.
79. 79 Leontsini E, Gil E, Kendall C, Clark GG. Effect of a community-based Aedes aegypti control programme on mosquito larval production sites in El Progreso, Honduras. Trans R Soc Trop Med Hyg 1993; 87: 267-71.
80. 80 Schofield CJ. The politics of malaria vector control. Bull Ent Res 1993; 83: 1-4.
81. 81 Rigau-Pérez JG, Gubler DJ. Surveillance for dengue and dengue hemorrhagic fever. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Wallingford, UK: CAB International, 1997: 405-23.
82. 82 Halstead SB, Shepard DS. Dengue (with notes on yellow fever and Japanese encephalitis). In: Jamison DT, ed. Disease control priorities in the developing countries. New York: Oxford University Press, 1993: 303-20.
83. 83 Meltzer MI, Rigau-Pérez JG, Clark GG, Reiter P, Gubler DJ. Using disability-adjusts life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am J Trop Med Hyg 1998; 59: 265-71.